Experts’ opinion for improving global adolescent vaccination rates: a call to action

Accepted/In Press date: 21 October 2019

e-pub ahead of print date: 18 February 2020

Published date: 1 April 2020

Additional Information: Funding Information: Medical writing support was provided by Judith Kandel, PhD, at Complete Healthcare Communications, LLC (North Wales, PA), a CHC Group Company, and was funded by Pfizer Inc. This work and the Advancing Adolescent Health Forum were sponsored by Pfizer Inc. Funding Information: All authors received honoraria, paid either to themselves or to their institutions, from Pfizer for participation in and/or travel to the Advancing Adolescent Health Spring Forum. In addition, CA has received honoraria for lecturing and/or as a member of advisory boards from MSD, Pfizer, and Sanofi Pasteur. JD-D has received honoraria from Sanofi Pasteur, Pfizer, and GSK for board membership and lectures, paid both to him and his institution, and has grants or pending grants from MSD awarded to his institution. EE has received honoraria as a past member of an IDMC for HPV vaccine from GSK. FR has been a speaker on industry-sponsored symposia organized by Pfizer and MSD and a member of advisory boards organized by Pfizer and GSK, with honoraria paid to Associação de Saúde Infantil de Coimbra (ASIC), and has an unrestricted research grant from Pfizer awarded to Associação de Saúde Infantil de Coimbra (ASIC). The honorarium for FR’s participation in the Advancing Adolescent Health Spring Forum was paid to Associação de Saúde Infantil de Coimbra (ASIC). SNF’s employers (University and Hospital) have received honoraria for his participation in advisory boards organized by vaccine and antimicrobial agent manufacturers (including Pfizer), and for his participation as a speaker in an industry-sponsored symposium (Pfizer); the University or Hospital has also received grants or pending grants for SNF’s role as a principal investigator for contract commercial clinical trials for multiple pharmaceutical companies, including Pfizer, and as a principal investigator for an investigator-led clinical study funded by Pfizer. AK has no additional disclosures. GSM has been an investigator, on behalf of his institution, on clinical trials funded by GSK, Merck, Novartis, Pfizer, Sanofi Pasteur, and Seqirus, and he has received honoraria from these companies for service on advisory boards. He has also received honoraria from Pfizer and Sanofi for non-branded presentations. TFS has received honoraria from Pfizer, Sanofi Pasteur, and Biogen for lecturing and from GSK and Pfizer as a member of advisory boards, and has received honoraria from GSK and Pfizer for conducting clinical vaccine trials. CWO has received honoraria for lecturing and/or as a member of advisory boards from AstraZeneca, Baxter, GSK, Medimmune, MSD, Pfizer, Sanofi Pasteur, and Seqirus. DTaP Publisher Copyright: © 2020, The Author(s).

Keywords: Adolescence, Immunization, Preventive healthcare, Vaccination, Vaccine-preventable diseases

Local EPrints ID: 438548

URI: http://eprints.soton.ac.uk/id/eprint/438548

DOI: doi:10.1007/s00431-019-03511-8

ISSN: 0340-6199

PURE UUID: 6f805a6a-62c8-4894-8ad2-193f87352f45

ORCID for Saul Faust: orcid.org/0000-0003-3410-7642

Date deposited: 16 Mar 2020 17:30

Last modified: 17 Mar 2024 05:10